Figure 6.

qRT-PCR assessment of ELMO1 knock-down. RMS cells were treated with nanoparticles coated with PEI (PEI- HMSNP/WMSNP), or non-targeting (NT) siRNA, or ELMO1 targeted siRNA. The lipid transfection agent, DharmaFECT, was compared with MSNPs of different morphologies for efficacy. The fold-difference, as determined by qRT-PCR, is shown. Data are presented as the mean ± SD of triplicate samples. Significance was tested using a two tailed t-test compared to the cells treated with ELMO1@DharmaFECT for each cell line (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005).